HRMY vs JAZZ vs SUPN vs AVPT vs ACAD

For growth investors, AvePoint, Inc.

(AVPT) is the stronger pick with 26. 9% revenue growth year-over-year, versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Harmony Biosciences Holdings, Inc. (HRMY) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 9x versus AvePoint, Inc. at 68. 8x. On forward P/E, Harmony Biosciences Holdings, Inc. is actually cheaper at 9. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Supernus Pharmaceuticals, Inc.

(SUPN) delivered a total return of +78. 0%, compared to +1. 7% for AvePoint, Inc. (AVPT). Over 10 years, the gap is even starker: SUPN returned +228. 4% versus ACAD's -22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Jazz Pharmaceuticals plc (JAZZ) is the lower-risk stock at 0.

65β versus ACADIA Pharmaceuticals Inc. 's 1. 26β — meaning ACAD is approximately 94% more volatile than JAZZ relative to the S&P 500. On balance sheet safety, AvePoint, Inc. (AVPT) carries a lower debt/equity ratio of 2% versus 126% for Jazz Pharmaceuticals plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AvePoint, Inc.

(AVPT) is pulling ahead at 26. 9% versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). On earnings-per-share growth, the picture is similar: AvePoint, Inc. grew EPS 193. 8% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -8. 3% for Jazz Pharmaceuticals plc — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HRMY leads at 24. 0% versus -5. 1% for SUPN. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Harmony Biosciences Holdings, Inc.

(HRMY) trades at 9. 0x forward P/E versus 50. 9x for ACADIA Pharmaceuticals Inc. — 42. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVPT: 69. 6% to $17. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Jazz Pharmaceuticals plc (JAZZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65)). Both have compounded well over 10 years (JAZZ: +53. 7%, ACAD: -22. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HRMY (Healthcare) and JAZZ (Healthcare) and SUPN (Healthcare) and AVPT (Technology) and ACAD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HRMY is a small-cap high-growth stock; JAZZ is a mid-cap quality compounder stock; SUPN is a small-cap quality compounder stock; AVPT is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.